The Progression of Targeted Therapies:
Addressing & Surmounting Complexities in Clinical Development
About this webinar
Targeted therapies are currently the focus of much anti-cancer drug development. They are a cornerstone of precision medicine, using information about a person’s genes and proteins to prevent, diagnose and treat disease. While these therapies show great promise, they are also very complex. These immuno-oncology and cytostatic treatments often require different assumptions and factors to be tested compared to traditional, early safety-based trials for cytotoxic agents. Clinical trial design is a critical factor that can make or break success. Careful foresight in initial stages can impact data quality and trial duration.
This webinar will address leading therapies in novel oncology trials. It will provide an in-depth perspective on what drug developers can do to find the right patients. It will offer insights into just how important biomarkers and companion diagnostics may be in targeted therapy clinical trials.
Attendees will gain important insights from experts developing some of the most innovative oncology clinical trials today.
Who should attend
- Clinical R&D
- Clinical Research
- Clinical Pharmacology
- Clinical Operations
- Project Management
- Regulatory Affairs
- Medical Affairs
What you will learn
- The current landscape and direction of novel oncology therapies
- Evaluating and selecting the optimum trial design for targeted therapies such as immunotherapy, monoclonal antibodies and gene therapy
- Feasibility considerations, including advancements in resourcing and technology to help find and recruit patients and the increasing impact of COVID-19
- The significance that biomarkers and companion diagnostics play in the development of targeted therapies
Featured Speakers
Deb Kientop, MBA
Kientop brings over 25 years of experience in oncology drug development. She started in the cancer research labs at the University of Wisconsin and then moved into business development, medical affairs and clinical development roles within pharma and CRO. Her career has included thought leader engagement, product lifecycle planning, strategy development and execution for proposals and bid defenses, as well as corporate strategy and alliance management. Through her work with oncology investigators and patient advocacy organizations, she has been able to incorporate insights into patient-centric development strategies. Kientop is also a published author and cancer patient advocate.
Prior to joining Synteract, Kientop was the Vice President of Life Sciences at Inteliquet, a healthcare technology company. Previously, she held senior director strategy positions at two large CROs, as well as numerous biopharmaceutical organizations including MedImmune, MGI Pharma and Eisai.
Kientop holds a Bachelor of Science in Pharmacology and Toxicology and a Master of Business Administration from the University of Wisconsin.
Partner for this event
Synteract
With employees across 21 countries, Synteract is an innovative, full-service CRO supporting biopharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and 750,000 patients. Greater than 245 of its 4,000 studies have been in pediatric populations. In addition to pediatrics clinical trials, Synteract offers a notable depth of therapeutic expertise in dermatology, neurodegenerative, oncology and immunotherapy and rare/orphan disease studies.
Related webinars
More from Synteract.
Closing the Gap: Broadening Representation in Clinical Trials
Forward-Focused Oncology: Applying Lessons Learned from COVID to Strengthen Oncology Clinical Trials
The Critical Impact of Rater Training in Dermatology Clinical Trials
Natural History Data and the Path to Registration in Pediatric Rare Disease Research
Rare Cancers: Special Considerations for Complex Clinical Studies
Leveraging Virtual Photography Solutions to Advance Dermatology Clinical Trials
Navigating the Current Landscape for Successful Dermatology Trials
Achieving Scalability and Reducing Costs with an FSP Model
Optimizing Clinical Trials Using Adaptive Design: Early Alignment for Success
Business Continuity in Drug Development Due to the COVID-19 Pandemic
Addressing the Rapidly Evolving Vaccine Development Landscape
Assessing the Competition in Rare Disease Clinical Trials: The Need for a Thorough Feasibility Strategy
